Ruffer LLP Makes New $6.41 Million Investment in Royalty Pharma PLC $RPRX

Key Points

• Ruffer LLP has made a new investment in Royalty Pharma PLC, purchasing 177,931 shares valued at approximately $6.41 million.
• Royalty Pharma recently reported $1.14 earnings per share for the quarter, beating expectations, though revenue was below estimates at $578.67 million.
• The company announced a quarterly dividend of $0.22 per share, with a dividend yield of 2.5% and a payout ratio of 50.87%.

Ruffer LLP bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 177,931 shares of the biopharmaceutical company's stock, valued at approximately $6,411,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Louisbourg Investments Inc. acquired a new stake in shares of Royalty Pharma during the first quarter worth $28,000. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 414 shares during the period. Summit Securities Group LLC acquired a new stake in shares of Royalty Pharma during the first quarter worth $36,000. WPG Advisers LLC bought a new position in shares of Royalty Pharma during the first quarter worth about $39,000. Finally, Allworth Financial LP grew its position in shares of Royalty Pharma by 41.6% during the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 452 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX opened at $35.77 on Thursday. Royalty Pharma PLC has a 52-week low of $24.05 and a 52-week high of $38.00. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average price of $36.33 and a 200 day moving average price of $34.41. The firm has a market capitalization of $20.86 billion, a PE ratio of 20.68, a P/E/G ratio of 2.26 and a beta of 0.58.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The company had revenue of $578.67 million during the quarter, compared to analyst estimates of $750.06 million. On average, sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were given a dividend of $0.22 per share. The ex-dividend date was Friday, August 15th. This represents a $0.88 annualized dividend and a dividend yield of 2.5%. Royalty Pharma's dividend payout ratio (DPR) is 50.87%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several recent research reports. Morgan Stanley upped their price target on shares of Royalty Pharma from $51.00 to $54.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Citigroup upped their price target on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Saturday, September 13th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $48.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.